Investors
Quarterly Reports
Q2 2019 Report
Monday, 19 AugustFjordalleen 16, 5. floor, Aker Brygge, OsloThe webcast will be streamed LIVE and the recording will be available after LIVE session is finished.
Link to live webcastCorporate Presentation
H.C. Wainwright 21st Annual Global Life Sciences Conference
Sept 10th, 2019
Read More
Scientific Presentations
ESMO 2019, Oddbjørn Straume et al
30 September 2019Barcelona, Spain
Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Read More
Annual Report 2018
BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.
Our annual report
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159